Roche Reports Phase 3 extension Data for Cemiplimab in Heart failure

Roche today announced Phase 3 extension results for cemiplimab in patients with heart failure. The study demonstrated that cemiplimab reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of heart failure and support the continued development of cemiplimab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.